Nexalin Technology

Nexalin Technology Forward P/E

The Forward P/E Ratio of Nexalin Technology (NXL) as of Nov 19, 2026 is -1.03. In the previous year, Forward P/E Ratio was -1.11 — a change of -7.48% (higher).

Forward P/E

-1.03

YoY

-7.48%

Last updated:

Forward P/E Ratio of Nexalin Technology is 2025 -1.03 . Forward P/E Ratio of Nexalin Technology was 2024 -1.11 . It decreases by -7.48% higher compared to the previous year.

The Nexalin Technology Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-1.68 USD
Jan 1, 2020
-2.48 USD
Jan 1, 2021
-1.39 USD
Jan 1, 2022
-4.97 USD
Jan 1, 2023
-1.82 USD
Jan 1, 2024
-1.11 USD
Jan 1, 2025
-1.03 USD
The Nexalin Technology Forward P/E history
YEARForward P/EYoY
-1.03-7.48%
-1.11-38.89%
-1.82-63.48%
-4.97+257.99%
-1.39-44.00%
-2.48+47.53%
-1.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Forward P/E Ratio of Nexalin Technology is -1.03 in 2025.

Forward P/E Ratio of Nexalin Technology changed from -1.11 to -1.03, representing a -7.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Nexalin Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nexalin Technology

All Key Metrics — Nexalin Technology